CN1304375C - 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物 - Google Patents
用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物 Download PDFInfo
- Publication number
- CN1304375C CN1304375C CNB008143870A CN00814387A CN1304375C CN 1304375 C CN1304375 C CN 1304375C CN B008143870 A CNB008143870 A CN B008143870A CN 00814387 A CN00814387 A CN 00814387A CN 1304375 C CN1304375 C CN 1304375C
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- alkyl
- jnk
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37823499A | 1999-08-19 | 1999-08-19 | |
| US09/378234 | 1999-08-19 | ||
| US09/642,557 US7119114B1 (en) | 1999-08-19 | 2000-08-18 | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
| US09/642557 | 2000-08-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1379763A CN1379763A (zh) | 2002-11-13 |
| CN1304375C true CN1304375C (zh) | 2007-03-14 |
Family
ID=23492297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008143870A Expired - Fee Related CN1304375C (zh) | 1999-08-19 | 2000-08-19 | 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1218347A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003532626A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20080028516A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1304375C (cg-RX-API-DMAC7.html) |
| AU (1) | AU780306B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2383268A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1053107A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ517578A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001012609A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200201312B (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119114B1 (en) | 1999-08-19 | 2006-10-10 | Signal Pharmaceuticals, Llc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
| US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| WO2002083648A1 (fr) | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Nouveau compose a base de 1h-indazole |
| US7018999B2 (en) | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
| WO2003010164A1 (en) | 2001-07-23 | 2003-02-06 | Applied Research Systems Ars Holding N.V. | Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| US7390797B2 (en) | 2002-02-28 | 2008-06-24 | Eisai Co., Ltd. | Fused indazole compounds |
| NZ535349A (en) | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌 |
| EP1490365B1 (en) | 2002-03-28 | 2010-02-10 | Eisai R&D Management Co., Ltd. | Azaindoles as inhibitors of c-jun n-terminal kinases |
| KR20040101398A (ko) * | 2002-04-05 | 2004-12-02 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 점액 과다분비의 치료방법 |
| MXPA04011851A (es) * | 2002-05-30 | 2005-03-31 | Celgene Corp | Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos. |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| US20040092568A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
| US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| US7612086B2 (en) | 2003-05-16 | 2009-11-03 | Eisai R & D Management Co. Ltd. | JNK inhibitors |
| EP1684690A4 (en) * | 2003-11-06 | 2008-10-15 | Celgene Corp | METHODS OF USE AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS |
| WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
| US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
| JP2008520730A (ja) * | 2004-11-23 | 2008-06-19 | セルジーン・コーポレーション | 中枢神経系傷害の治療用jnk阻害剤 |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
| US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
| KR102484810B1 (ko) | 2016-05-25 | 2023-01-05 | (주)아모레퍼시픽 | 피부 미백용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2167626A1 (cg-RX-API-DMAC7.html) * | 1972-01-03 | 1973-08-24 | Basf Ag | |
| FR2401915A1 (fr) * | 1977-09-02 | 1979-03-30 | Ciba Geigy Ag | Procede pour la preparation de pyrazolanthrones portant un substituant sur la position 3 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH538528A (de) * | 1968-11-07 | 1973-06-30 | Hoechst Ag | Verfahren zur Herstellung von faserreaktiven Farbstoffen |
| DE2558813C2 (de) * | 1975-12-27 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Lichtempfindliches Gemisch mit synergistischem Initiatorsystem |
-
2000
- 2000-08-19 KR KR1020087006016A patent/KR20080028516A/ko not_active Withdrawn
- 2000-08-19 KR KR1020027002168A patent/KR100835700B1/ko not_active Expired - Fee Related
- 2000-08-19 HK HK02109283.5A patent/HK1053107A1/zh unknown
- 2000-08-19 JP JP2001517507A patent/JP2003532626A/ja active Pending
- 2000-08-19 WO PCT/US2000/022727 patent/WO2001012609A1/en not_active Ceased
- 2000-08-19 EP EP00955709A patent/EP1218347A1/en not_active Withdrawn
- 2000-08-19 NZ NZ517578A patent/NZ517578A/en unknown
- 2000-08-19 AU AU67863/00A patent/AU780306B2/en not_active Ceased
- 2000-08-19 CA CA002383268A patent/CA2383268A1/en not_active Abandoned
- 2000-08-19 CN CNB008143870A patent/CN1304375C/zh not_active Expired - Fee Related
-
2002
- 2002-02-15 ZA ZA200201312A patent/ZA200201312B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2167626A1 (cg-RX-API-DMAC7.html) * | 1972-01-03 | 1973-08-24 | Basf Ag | |
| FR2401915A1 (fr) * | 1977-09-02 | 1979-03-30 | Ciba Geigy Ag | Procede pour la preparation de pyrazolanthrones portant un substituant sur la position 3 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100835700B1 (ko) | 2008-06-09 |
| KR20080028516A (ko) | 2008-03-31 |
| ZA200201312B (en) | 2003-02-17 |
| JP2003532626A (ja) | 2003-11-05 |
| EP1218347A1 (en) | 2002-07-03 |
| CN1379763A (zh) | 2002-11-13 |
| CA2383268A1 (en) | 2001-02-22 |
| AU780306B2 (en) | 2005-03-17 |
| KR20020038733A (ko) | 2002-05-23 |
| NZ517578A (en) | 2004-02-27 |
| WO2001012609A1 (en) | 2001-02-22 |
| HK1053107A1 (zh) | 2003-10-10 |
| AU6786300A (en) | 2001-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1379763A (zh) | 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物 | |
| CN1098838C (zh) | 被取代的N-(吲哚-2-羰基)-β-丙氨酰胺与作为抗糖尿病药的衍生物 | |
| CN100339080C (zh) | 抗病毒大环化合物 | |
| CN1145616C (zh) | 新的氨基三唑化合物,其制备方法及包含它们的药物组合物 | |
| CN1176651C (zh) | N-(3-苯并呋喃基)脲衍生物 | |
| CN1146543C (zh) | 凝血酶抑制剂 | |
| CN1906189A (zh) | 用于治疗呼吸系统疾病的1-乙酸-吲哚、-吲唑和-苯并咪唑衍生物 | |
| CN1168720C (zh) | 芳基链烷酰基哒嗪化合物 | |
| CN1688574A (zh) | 作为葡糖激酶(gk)激活剂的吲哚-3-甲酰胺 | |
| CN1387517A (zh) | 作为环加氧酶-2抑制剂的5-芳基-1h-1,2,4-三唑化合物及含有它们的药物组合物 | |
| CN1127486C (zh) | 二氮杂萘衍生物磷酸二酯酶4抑制剂 | |
| CN1223652A (zh) | 作为钠通道调节剂的环醚化合物 | |
| CN101035795A (zh) | 噻唑基二氢吲唑 | |
| CN1960979A (zh) | 作为mmp抑制剂用于治疗哮喘和慢性阻塞性肺病的三唑酮衍生物 | |
| CN101052634A (zh) | 作为vegf受体激酶抑制剂的邻氨基苯甲酰胺吡啶脲 | |
| CN1186485A (zh) | 吡咯衍生物以及医药组合物 | |
| CN1745065A (zh) | 4-氧代-3-(1-氧代-1h-异喹啉-2-基乙酰氨基)-戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途 | |
| CN1035255C (zh) | 杂三环衍生物 | |
| CN1612865A (zh) | 作为环加氧酶(cox)抑制剂的三唑衍生物 | |
| CN1993358A (zh) | 作为趋化因子受体拮抗剂的噻唑衍生物 | |
| CN1310909C (zh) | 新型杂芳基衍生物、其制备以及应用 | |
| CN1067072C (zh) | 三环化合物、它们的制备及其用途 | |
| CN1918148A (zh) | 取代的苯并咪唑和它们诱导细胞凋亡的用途 | |
| CN1245400C (zh) | N-取代苯并噻唑磺胺衍生物 | |
| CN1210273C (zh) | 取代的3-吡啶基-4-芳基吡咯及治疗和预防相关疾病的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |